Construction has begun to expand the National Institute for Bioprocessing Research and Training's (NIBRT) existing facility in Dublin.

This €21 million project will see an extended facility built to increase NIBRT's capacity and capability to conduct manufacturing-focused research and training in advanced therapeutics.

When complete and operational in the second quarter of 2023, the facility will accommodate around 25 new researchers and training staff and will serve new and existing NIBRT clients by providing research solutions to manufacturing challenges and staff training in the manufacturing of these highly innovative and complex medicines.

The development is funded by the Irish Government through IDA Ireland and incorporates 1,800 m2 of new space, including five research laboratories and state of the art training suites, into the existing NIBRT facility that will be dedicated to advanced therapeutics.

Tánaiste and Minister for Enterprise, Trade and Employment Leo Varadkar TD said: "Ireland is fast becoming a world leader in advanced therapeutics, the really high value, highly skilled work involved in making new vaccines and new treatments for rare and devastating diseases. In order to keep pace with what is always going to be a fast-developing area, we need to continuously invest in cutting-edge research and training for our workforce, so they can compete with the best on an international stage. So, I'm really happy to announce the start of this expansion today. The Government is investing €21m, which will give us five new research labs, two new training suites and accommodate 25 new researchers. The work being done here will make a real difference to thousands of people's lives."

-- Advertisement --

Speaking at today's announcement, NIBRT CEO Darrin Morrissey commented: "The role of NIBRT is to help the growth and development of the biopharma manufacturing sector in Ireland by providing cutting edge training and research solutions. NIBRT intends to further enhance our current capability by becoming a leader in the pioneering and fast-evolving area of advanced therapies and vaccines. It is an immensely exciting time for NIBRT. With this expansion, we expect to deliver training for many more potential and newly-hired biopharma staff, as well as considerable growth in our research activities. This has the potential to rapidly enhance Ireland's standing as a location of choice for advanced therapy and vaccine manufacturing."

The Irish biopharma industry continues to go from strength-to-strength, with over 20 new biologics manufacturing facilities developed across Ireland over the last decade and in excess of €12 billion in capital investment. The sector now supports over 40,000 high quality jobs with a diverse range of new opportunities currently available with the world's leading biopharma and biotech employers. 

Martin Shanahan, CEO IDA Ireland added: "The expansion of NIBRT to respond to innovation in the sector greatly adds to Ireland's reputation as a global location of excellence for next-generation biopharmaceutical products. IDA Ireland continues to partner with and support NIBRT to ensure that Ireland is well positioned to support companies in these emerging advanced therapeutic areas. Cell & Gene therapy is a core pillar in the developing field of Advanced Therapy Medicinal Products (ATMPs) which is widely considered as the next generation of pharmaceutical therapies. These products require highly innovative approaches to manufacturing and offer unparalleled opportunities in the treatment of disease."